Torrent Pharmaceuticals Limited , a leading Indian pharmaceutical company, has announced robust financial results for the first quarter, along with a significant leadership change.

Strong Financial Performance

The company reported impressive growth in its Q1 results:

• Revenue reached Rs. 3,178.00 crores, marking an 11% year-over-year increase
• Operating EBITDA rose by 14% to Rs. 1,032.00 crores
• Net profit after tax grew by 20% to Rs. 548.00 crores
• R&D spend increased by 16% to Rs. 157.00 crores

The company maintained a strong operating EBITDA margin of 32.50% and a gross margin of 76.00%.

Key Market Performance

Torrent Pharmaceuticals demonstrated growth across its major markets:

Appointment of New Managing Director

In a significant move, Torrent Pharmaceuticals' shareholders have approved the appointment of Aman Mehta as Managing Director and Whole-time Key Managerial Personnel for a 5-year term beginning August 1, 2025.

Aman Mehta's Background and Achievements

Aman Mehta brings a wealth of experience to his new role:

• Holds an economics degree from Boston University and an MBA from Columbia University
• Over 10 years of leadership experience across Torrent's Power and Pharma divisions
• Key achievements during his tenure as Whole-time Director include:
  • Expanding the field force from 3,600 to 6,400 medical representatives
  • Improving cardiac portfolio performance
  • Elevating the diabetes portfolio ranking from 11th to 6th position
  • Launching the Consumer Health Division
  • Overseeing R&D and operations functions
  • Successfully integrating acquisitions, including Unichem and Curatio Healthcare

Future Outlook

With strong financial results and new leadership in place, Torrent Pharmaceuticals is well-positioned for continued growth. The company's focus on chronic therapies, which account for about 76% of its India revenues, and its strong presence in international markets, particularly in Brazil and Germany, provide a solid foundation for future expansion.

The appointment of Aman Mehta as Managing Director is expected to bring fresh perspectives and strategic initiatives to drive the company's growth in the coming years. His experience in both the Power and Pharma sectors of the Torrent Group, coupled with his track record of successful acquisitions and market expansion, suggests a promising future for Torrent Pharmaceuticals.

As the pharmaceutical landscape continues to evolve, Torrent's commitment to R&D investment and focus on key therapeutic areas position it well to capitalize on emerging opportunities in the global pharmaceutical market.

Torrent Pharmaceuticals Limited , one of India's leading pharmaceutical companies, has announced robust financial results for the first quarter, along with a significant leadership change.

Strong Financial Performance

The company reported a 20% year-on-year increase in net profit, reaching Rs 548.00 crore for the quarter. This growth was driven by an 11% rise in revenue, which stood at Rs 3,178.00 crore.

Key financial highlights for Q1 include:

The company maintained a strong operating EBITDA margin of 32.5% and a gross margin of 76%.

Market Performance

Torrent Pharma outperformed in several key markets:

• India: Revenues grew by 11% to Rs 1,811.00 crore, outpacing the Indian Pharmaceutical Market (IPM) growth of 8%. The company's chronic business grew by 13%, compared to the IPM's 9% growth in this segment.

• Brazil: Revenues increased by 11% to Rs 218.00 crore, with constant currency growth of 16%. Torrent's growth of 14% outpaced the market growth of 5%.

• Germany: Revenues rose by 9% to Rs 308.00 crore, with constant currency growth of 1%.

• United States: The US business saw a significant 19% increase in revenues to Rs 308.00 crore, with constant currency growth of 16%.

Leadership Transition

In a separate announcement, Torrent Pharmaceuticals' shareholders approved the appointment of Aman Mehta as Managing Director and Whole-time Key Managerial Personnel for a 5-year term beginning August 1, 2025.

Aman Mehta, who holds an economics degree from Boston University and an MBA from Columbia University, has been with Torrent for over 10 years. During his tenure as Whole-time Director, he has led several key initiatives:

• Expanding the field force from 3,600 to 6,400 medical representatives
• Improving the cardiac portfolio performance
• Elevating the diabetes portfolio ranking from 11th to 6th position
• Launching the Consumer Health Division
• Overseeing R&D and operations functions

Mehta has also played crucial roles in integrating acquisitions, including Unichem and Curatio Healthcare.

Strategic Acquisition

Torrent Pharmaceuticals has entered into a definitive agreement to acquire a controlling stake in J.B. Chemicals & Pharmaceuticals Limited (JB Pharma). The transaction, subject to regulatory approvals, will be executed in two phases:

1. Acquisition of up to 46.39% equity stake at Rs 1,600.00 per share, followed by a mandatory open offer for up to 26% additional stake.
2. Merger of JB Pharma with Torrent Pharmaceuticals through a scheme of arrangement.

This strategic move is expected to further strengthen Torrent's position in the pharmaceutical market.

As Torrent Pharmaceuticals continues to grow and evolve, the combination of strong financial performance, strategic leadership changes, and expansion initiatives positions the company for continued success in the competitive pharmaceutical landscape.